AVOS Life Sciences

Tables and Figures - Multiple Sclerosis

Tables

Table 1: Classification and Description of Multiple Sclerosis Sub-Types 13
Table 2: High-Risk Populations for Developing MS 15
Table 3: AVOS U.S. Multiple Sclerosis Patient Population Model, 2005-2014E 18
Table 4: AVOS U.S. Multiple Sclerosis Market Model, 2005-2014E 20
Table 5: Marketed Products in the United States 33
Table 6: Factors Shaping the Market for Oral Treatments 37
Table 7: Comparison of Key Phase III Pipeline Products with Avonex 38
Table 8: Quantitative Assessment of Key Phase III Pipeline Products Versus Avonex 39
Table 9: Top Ten Unmet Medical Needs in MS 41
Table 10: Five-Year Forecasts of Future Market Trends for Inline Products: 2008E-2014E 42
Table 11: Overview of Inline Products 43
Table 12: Avonex-Revenue Model 44
Table 13: Avonex Commercial Strength 44
Table 14: Betaseron-Revenue Model 46
Table 15: Betaseron Commercial Strength 46
Table 16: Recent Betaseron Studies 47
Table 17: Rebif-Revenue Model 48
Table 18: Rebif Commercial Strength 48
Table 19: Copaxone-Revenue Model 50
Table 20: Copaxone Commercial Strength 50
Table 21: Tysabri-Revenue Model 52
Table 22: Tysabri Commercial Strength 52
Table 23: Risks Threatening Tysabri's Success 54
Table 24: Novantrone Commercial Strength 55
Table 25: Extavia-Revenue Model 56
Table 26: Betaseron Studies Supporting Extavia 57
Table 27: Cladribine-Revenue Model 58
Table 28: Ongoing Cladribine Clinical Trials 58
Table 29: FTY720-Revenue Model 60
Table 30: Ongoing FTY720 Clinical Trials 61
Table 31: Campath-Revenue Model 62
Table 32: Ongoing Campath Clinical Trials 63
Table 33: Laquinimod-Revenue Model 64
Table 34: Ongoing Laquinimod Clinical Trials 64
Table 35: Teriflunomide-Revenue Model 66
Table 36: Drugs In Development 71
Table 37: Overview of Inline and Pipeline MS Therapies 74

Figures

Figure 1: U.S. Theoretical Patient Population Breakdown by Sub-type of Multiple Sclerosis 15
Figure 2: AVOS Multiple Sclerosis Population Projections by Year, 2005-2014E 19
Figure 3: The Diagnosis Decision Tree for Multiple Sclerosis 24
Figure 4: Treatment Decision Tree: Mild-to-Moderate Multiple Sclerosis 25
Figure 5: Treatment Decision Tree: Aggressive Multiple Sclerosis 26
Figure 6: Product Specific Criteria of the Drug Selection Process 29
Figure 7: AVOS Physician Panel Product Ratings 30
Figure 8: Timeline of Major Past Multiple Sclerosis Market Events 34
Figure 9: Estimated Timeline of Major Future Multiple Sclerosis Market Events 34
Figure 10: Transforming Market Catalysts Shaping the Future of the MS Market 35
Figure 11: Avonex U.S. Market Share Forecast 44
Figure 12: Avonex U.S. Revenue Forecast 44
Figure 13: Betaseron U.S. Market Share Forecast 46
Figure 14: Betaseron U.S. Revenue Forecast 46
Figure 15: Rebif U.S. Market Share Forecast 48
Figure 16: Rebif U.S. Revenue Forecast 48
Figure 17: Copaxone U.S. Market Share Forecast 50
Figure 18: Copaxone U.S. Revenue Forecast 50
Figure 19: Tysabri U.S. Market Share Forecast 52
Figure 20: Tysabri U.S. Revenue Forecast 52
Figure 21: Timeline of Tysabri Events 53
Figure 22: Extavia U.S. Market Share Forecast 56
Figure 23: Extavia U.S. Revenue Forecast 56
Figure 24: Cladribine U.S. Market Share Forecast 58
Figure 25: Cladribine U.S. Revenue Forecast 58
Figure 26: FTY720 U.S. Market Share Forecast 60
Figure 27: FTY720 U.S. Revenue Forecast 60
Figure 28: Campath U.S. Market Share Forecast 62
Figure 29: Campath U.S. Revenue Forecast 62
Figure 30: Laquinimod U.S. Market Share Forecast 64
Figure 31: Laquinimod U.S. Revenue Forecast 64
Figure 32: Teriflunomide U.S. Market Share Forecast 66
Figure 33: Teriflunomide U.S. Revenue Forecast 66
Figure 34: Clinical Success Rates of MS Disease Modifying Agents: 1995-Present 70
Cover

Production date: July 2008

Order

Print Copy - $5,000

Single Site license PDF - $7,000

Global License PDF - $9,995

Contact Information:

If you wish to see sample pages or to learn more about AVOS Therapeutic Market Reports, contact Mike Goodman
919-475-9695
reports@avoslifesciences.com